{
    "id": 25767,
    "fullName": "DTL positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "DTL positive indicates the presence of the DTL gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 51514,
        "geneSymbol": "DTL",
        "terms": [
            "DTL",
            "CDT2",
            "DCAF2",
            "L2DTL",
            "RAMP"
        ]
    },
    "variant": "positive",
    "createDate": "11/29/2016",
    "updateDate": "11/29/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9440,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing Dtl demonstrated sensitivity to MLN4924, resulting in inhibition of cell proliferation in culture and suppressed tumor growth in xenograft models (PMID: 27333051).",
            "molecularProfile": {
                "id": 26847,
                "profileName": "DTL positive"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9442,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF and NRAS wild-type and expressing DTL demonstrated tumor growth inhibition in xenograft models when treated with MLN4924 (PMID: 27333051).",
            "molecularProfile": {
                "id": 26849,
                "profileName": "BRAF wild-type DTL pos NRAS wild-type"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MLN4924 and PLX4720 resulted in a synergistic effect in a melanoma cell line xenograft model resistant to BRAF inhibitors, and harboring a BRAF mutation and DTL expression (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 5017,
                "therapyName": "MLN4924 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9443,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and expressing DTL, and resistant to BRAF inhibitors, demonstrated sensitivity to MLN4924 in xenograft models, resulting in some inhibition of tumor growth (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26847,
            "profileName": "DTL positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26848,
            "profileName": "DTL pos NRAS act mut PDGFRA act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26849,
            "profileName": "BRAF wild-type DTL pos NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26850,
            "profileName": "BRAF mut DTL pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}